Friday, 16 October 2026European Markets

SALMAR Stock Was 11.69% Up On Thursday

Loading stream...

(VIANEWS) - The Market ended the session with SALMAR (SALM.OL) jumping 11.69% to kr521.80 on Thursday while Oslo Børs Benchmark Index_GI dropped 0.17% to kr1,219.16.

SALMAR's last close was kr467.20, 36.26% under its 52-week high of kr733.00.

About SALMAR

SalMar ASA, an aquaculture company, produces and sells farmed salmon in Asia, North America, Europe, and internationally. The company operates through Fish Farming, Sales & Industry, Icelandic Salmon, and SalMar Aker Ocean segments. It is involved in the broodstock, lumpfish, and smolt production activities; and marine-phase farming, harvesting, processing, and selling farmed salmon. SalMar ASA was founded in 1991 and is headquartered in Kverva, Norway.

Earnings Per Share

As for profitability, SALMAR has a trailing twelve months EPS of kr29.88.

PE Ratio

SALMAR has a trailing twelve months price to earnings ratio of 17.46. Meaning, the purchaser of the share is investing kr17.46 for every norwegian krone of annual earnings.

Yearly Top and Bottom Value

SALMAR's stock is valued at kr521.80 at 22:41 EST, way under its 52-week high of kr733.00 and way above its 52-week low of kr305.00.

Growth Estimates Quarters

The company's growth estimates for the present quarter is 80.6% and a drop 29.4% for the next.

More news about SALMAR (SALM.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com